Tevogen Bio To Become Publicly Listed On NYSE Via Business Combination With Semper Paratus Acquisition Corporation
Portfolio Pulse from Happy Mohamed
Tevogen Bio Inc. is set to become publicly listed on the NYSE through a business combination with Semper Paratus Acquisition Corporation. The transaction is expected to provide Tevogen Bio with access to capital markets and accelerate the development of its product, TVGN 489, a COVID-19 therapeutic solution. The combined company will be named Tevogen Bio Holdings Inc. and is expected to be listed on the NYSE under the ticker symbol 'TVGN'. The pro forma equity value of the combined company is expected to be approximately $1.2 billion, with the merger expected to be completed in Q4 2023.
June 29, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Semper Paratus Acquisition Corporation is merging with Tevogen Bio, which will result in the combined company being listed on the NYSE. This could potentially increase the value of LGST's shares.
The merger with Tevogen Bio could potentially increase the value of Semper Paratus Acquisition Corporation's shares as the combined company will be listed on the NYSE. This could attract more investors, leading to an increase in demand for the shares and subsequently, their price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100